BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 21171270)

  • 1. [Clinical features of benign prostatic hyperplasia complicated by chronic prostatitis].
    Chang DG; Li GS; Zhang PH; Wu TL; Mei XF; Cao J; Gao P
    Zhonghua Nan Ke Xue; 2010 Sep; 16(9):830-3. PubMed ID: 21171270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Expressions of SIgA and alpha 1-AR in benign prostatic hyperplasia combined with chronic prostatitis and their implications].
    Gao WJ; Wang YM; Wang CH; Yang XK; Wan L; Li WP
    Zhonghua Nan Ke Xue; 2013 Apr; 19(4):315-20. PubMed ID: 23678709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical significance of prostate specific antigen (PSA) and PSA density in the detection of T1a and T1b prostate cancer].
    Meguro N; Maeda O; Saiki S; Kinouchi T; Kuroda M; Usami M; Kotake T
    Hinyokika Kiyo; 1998 Sep; 44(9):639-43. PubMed ID: 9805668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Benign prostate hyperplasia with chronic prostatitis: an update].
    Ma Y; Zhang WL
    Zhonghua Nan Ke Xue; 2010 Jul; 16(7):646-50. PubMed ID: 20873602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Aggressiveness and extent of prostatic inflammation relates with serum PSA levels in type IV prostatitis].
    Man LB; Li GZ; Huang GL; Wang JW; Liu BY
    Zhonghua Nan Ke Xue; 2012 Aug; 18(8):710-4. PubMed ID: 22934516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Comparison of PSAD and PSAD-TZ value in prostatic hyperplasia and prostatic cancer].
    Fu Q; Yao DH; Jiang YQ
    Zhonghua Nan Ke Xue; 2002 Dec; 8(6):411-3. PubMed ID: 12593013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Changes in the levels of prostate-specific antigen and its molecular forms with alpha 1-antichymotrypsin in patients with benign prostatic hyperplasia].
    Grigor'ev ME; Mazo EB; Chekhonin VP
    Urol Nefrol (Mosk); 1998; (4):33-7. PubMed ID: 9727319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Significance of histological prostatitis in patients with urinary retention and underlying benign prostatic hyperplasia or adenocarcinoma of the prostate.
    van Vuuren SP; Heyns CF; Zarrabi AD
    BJU Int; 2012 Apr; 109(8):1194-7. PubMed ID: 21851551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Correlation of histological prostatitis with PSA, prostate volume, PSAD, IPSS, Qmax and PVR in BPH patients].
    Zhang HT; Xu Y; Chang JW; Zhang ZH; Liu RL; Ma BJ
    Zhonghua Nan Ke Xue; 2012 Mar; 18(3):208-11. PubMed ID: 22474983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A clinical analysis of benign prostatic hyperplasia with chronic prostatitis].
    Wu XJ; Yang LY; Zhang XZ
    Zhonghua Nan Ke Xue; 2008 Jun; 14(6):527-9. PubMed ID: 18649752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of interleukin-8 in expressed prostatic secretion as a reliable biomarker of inflammation in benign prostatic hyperplasia.
    Liu L; Li Q; Han P; Li X; Zeng H; Zhu Y; Wei Q
    Urology; 2009 Aug; 74(2):340-4. PubMed ID: 19464042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The ratio of prostate-specific antigen (PSA) to prostate volume (PSA density) as a parameter to improve the detection of prostate carcinoma in PSA values in the range of < 4 ng/mL.
    Stephan C; Stroebel G; Heinau M; Lenz A; Roemer A; Lein M; Schnorr D; Loening SA; Jung K
    Cancer; 2005 Sep; 104(5):993-1003. PubMed ID: 16007682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The role of prostate specific antigen in diagnosis of localized adenocarcinoma of the prostate. Nara Uro-Oncology Research Group].
    Hirao Y; Ozono S; Kagebayashi Y; Yoshi M; Tani Y; Uemura H; Momose H; Okajima E
    Hinyokika Kiyo; 1996 Oct; 42(10):795-804. PubMed ID: 8951478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Expression of estrogen receptor beta in benign prostatic hyperplasia complicated by chronic prostatitis].
    Yang GQ; Li SW; Zheng H; Zhang WB; Hu WL; Zheng XM
    Zhonghua Nan Ke Xue; 2009 Apr; 15(4):314-7. PubMed ID: 19472903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate specific antigen density for discriminating prostate cancer from benign prostatic hyperplasia in the gray zone of prostate-specific antigen.
    Uno H; Koide T; Kuriyama M; Ban Y; Deguchi T; Kawada Y
    Hinyokika Kiyo; 1999 Jul; 45(7):457-61. PubMed ID: 10466060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [LUTS in BPH patients with histological prostatitis before and after transurethral resection of the prostate].
    Huang XH; Qin B; Liang YW; Wu QG; Li CZ; Wei GS; Ji HC; Liang YB; Chen HQ; Guan T
    Zhonghua Nan Ke Xue; 2013 Jan; 19(1):35-9. PubMed ID: 23469659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ratio of free-to-total prostate specific antigen in serum cannot distinguish patients with prostate cancer from those with chronic inflammation of the prostate.
    Jung K; Meyer A; Lein M; Rudolph B; Schnorr D; Loening SA
    J Urol; 1998 May; 159(5):1595-8. PubMed ID: 9554361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum.
    Becker C; Piironen T; Pettersson K; Björk T; Wojno KJ; Oesterling JE; Lilja H
    J Urol; 2000 Jan; 163(1):311-6. PubMed ID: 10604382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of prostatic carcinoma: the role of TRUS, TRUS guided biopsy, digital rectal examination, PSA and PSA density.
    Men S; Cakar B; Conkbayir I; Hekimoglu B
    J Exp Clin Cancer Res; 2001 Dec; 20(4):473-80. PubMed ID: 11876539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Does plasmatic dilution influence the validity of PSA-tests?].
    Rohde D; Mihelcic V
    Aktuelle Urol; 2007 Mar; 38(2):137-43. PubMed ID: 17390276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.